JP7602272B2 - Ｋｒａｓ関連がんを治療する方法 - Google Patents

Ｋｒａｓ関連がんを治療する方法 Download PDF

Info

Publication number
JP7602272B2
JP7602272B2 JP2022511096A JP2022511096A JP7602272B2 JP 7602272 B2 JP7602272 B2 JP 7602272B2 JP 2022511096 A JP2022511096 A JP 2022511096A JP 2022511096 A JP2022511096 A JP 2022511096A JP 7602272 B2 JP7602272 B2 JP 7602272B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
kras
egfr
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022511096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545005A (ja
JP2022545005A5 (enExample
Inventor
ケー．ニャティ ムケシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2022545005A publication Critical patent/JP2022545005A/ja
Publication of JP2022545005A5 publication Critical patent/JP2022545005A5/ja
Application granted granted Critical
Publication of JP7602272B2 publication Critical patent/JP7602272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022511096A 2019-08-22 2020-08-20 Ｋｒａｓ関連がんを治療する方法 Active JP7602272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890119P 2019-08-22 2019-08-22
US62/890,119 2019-08-22
PCT/US2020/047090 WO2021034992A1 (en) 2019-08-22 2020-08-20 Method of treating kras-associated cancers

Publications (3)

Publication Number Publication Date
JP2022545005A JP2022545005A (ja) 2022-10-24
JP2022545005A5 JP2022545005A5 (enExample) 2023-08-28
JP7602272B2 true JP7602272B2 (ja) 2024-12-18

Family

ID=74660044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511096A Active JP7602272B2 (ja) 2019-08-22 2020-08-20 Ｋｒａｓ関連がんを治療する方法

Country Status (11)

Country Link
US (1) US20220273643A1 (enExample)
EP (1) EP4017489B1 (enExample)
JP (1) JP7602272B2 (enExample)
KR (1) KR20220050143A (enExample)
CN (2) CN119454706A (enExample)
AU (1) AU2020334069B2 (enExample)
BR (1) BR112022003165A2 (enExample)
CA (1) CA3150759A1 (enExample)
IL (1) IL290454B2 (enExample)
MX (1) MX2022002108A (enExample)
WO (1) WO2021034992A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
KR20240016250A (ko) * 2021-04-02 2024-02-06 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료를 위한 병용요법
WO2023003417A1 (ko) * 2021-07-22 2023-01-26 국립암센터 Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546421A (ja) 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤
JP2021514001A (ja) 2018-02-23 2021-06-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ Ｅｇｆｒ二量体撹乱剤およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546421A (ja) 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤
JP2021514001A (ja) 2018-02-23 2021-06-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ Ｅｇｆｒ二量体撹乱剤およびその使用

Also Published As

Publication number Publication date
EP4017489A1 (en) 2022-06-29
EP4017489A4 (en) 2023-08-23
AU2020334069B2 (en) 2026-02-19
CA3150759A1 (en) 2021-02-25
KR20220050143A (ko) 2022-04-22
EP4017489C0 (en) 2025-05-07
BR112022003165A2 (pt) 2022-05-17
WO2021034992A1 (en) 2021-02-25
CN114286676A (zh) 2022-04-05
JP2022545005A (ja) 2022-10-24
IL290454B1 (en) 2025-08-01
MX2022002108A (es) 2022-03-17
IL290454B2 (en) 2025-12-01
US20220273643A1 (en) 2022-09-01
IL290454A (en) 2022-04-01
EP4017489B1 (en) 2025-05-07
AU2020334069A1 (en) 2022-03-24
CN119454706A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
EP4017489B1 (en) Dgd1202 for use in the treatment of kras-mutated cancers
JP7466795B2 (ja) Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
JP7086251B2 (ja) ヘテロ環式化合物およびそれらの使用
TWI818917B (zh) 巨環化合物及其用途
US20220340572A1 (en) Egfr dimer disruptors and use of the same
JP2023515689A (ja) Ｅｇｆｒ、ｋｒａｓ、ｂｒａｆ、及び他の標的の阻害剤、並びにその使用
JP2022058398A (ja) Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４
CN109820853B (zh) 取代的杂环化合物在制备治疗癌症药物中的用途
CN115397413A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
JP2021121611A (ja) アピリモドを用いる癌の処置方法
CN110891576A (zh) 使用包含parp抑制剂、替莫唑胺和/或放射疗法的组合治疗癌症
CN114364677A (zh) 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物
CA3117838A1 (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
TW202435873A (zh) 作為ｄｎａ聚合酶θ抑制劑之噻二唑基衍生物及其用途
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
CN112237579B (zh) 药物组合及其用途
JP2020533316A (ja) アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法
TW202535405A (zh) 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑
TW202132285A (zh) 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
EP3324974B1 (en) Compounds, compositions, methods for treating diseases, and methods for preparing compounds
HK40072817A (en) Method of treating kras-associated cancers
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
WO2016197981A1 (zh) 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
JP2024047569A (ja) Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
CN117561255A (zh) 作为mek抑制剂的3,4-二氢-2,7-萘啶-1,6(2h,7h)-二酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241129

R150 Certificate of patent or registration of utility model

Ref document number: 7602272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150